PARP Inhibition in Prostate Cancer: An Evolving Paradigm and the Role of the Practicing Urologist

Join an expert urologist and medical oncologist for this webinar featuring dynamic, case-based presentations and discussion on the urologist’s role in leveraging PARP inhibitor–based therapy for patients with metastatic prostate cancer. Get up to date on testing strategies, the latest data on monotherapy and combination therapy with PARP inhibitors, and identifying patients eligible for ongoing clinical trials.

To Register: On the Event Dates page click a date/time, click the blue Register button in the upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Agenda

  • Welcome and Introduction
  • Case 1: When to Test
    • Tissue-based vs blood-based testing
    • Practical issues in testing of biopsy and surgical specimens
    • Genetic counseling
  • Case 2: When to Treat
    • Selecting patients for PARP inhibitor–based therapy
    • PARP inhibitor monotherapy
    • PARP inhibitor combinations in metastatic prostate cancer
    • Key ongoing clinical trials
  • Audience Question and Answer Session

Faculty

Faculty
Stephen Freedland, MD

Professor
Department of Surgery
Department of Urology
Cedars-Sinai Medical Center
Los Angeles, California

Faculty
Rana R. McKay, MD

Associate Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
University of California, San Diego
Genitourinary Oncology Team Lead
Moores Cancer Center
La Jolla, California

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and competence of learners to integrate PARP inhibitors and recent findings into the treatment of patients with prostate cancer.

Target Audience
This program is intended for urologists and other healthcare professionals who care for patients with prostate cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Describe the medical need and rationale for PARP inhibitors and PARP inhibitor–based combinations in prostate cancer, with or without DNA damage repair alterations
  • Obtain tumor tissue and assure that it is tested for DNA damage repair alterations to meet the currently approved use of PARP inhibitors for the treatment of prostate cancer
  • Appraise the available clinical evidence and clinical trial strategies using PARP inhibitor–based combinations for prostate cancer in metastatic and earlier stages of disease with or without DNA damage repair alterations
  • Identify patients suitable for enrollment on ongoing clinical studies investigating PARP inhibitor combinations in prostate cancer

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.